Premier Biotech Labs, LLC

Premier Biotech Labs, LLC was paid $41.43M by Medicaid between Jan 2018 and Dec 2024, across 37 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 32% of everything it billed.

33Billing provider infoPREMIER BIOTECH LABS, LLC
MINNEAPOLIS, MN 55414

33aNPI1700280971assigned 10/17/2014

33bProvider typeClinical Medical Laboratory

28Total paid$41.43M

24GClaims784,980

24DCodes billed37

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Minnesota

Rank by total paid#3 of 69

Median peer was paid$48K

This provider vs. median859×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	31,523	$1.24M
2019	126,147	$7.34M
2020	112,948	$6.91M
2021	152,544	$6.89M
2022	123,127	$6.52M
2023	135,190	$6.81M
2024incomplete	103,501	$5.71M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	32%	366,254	213,538	$13.15M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	28%	163,346	109,233	$11.46M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	20%	72,155	23,448	$8.21M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	10%	32,787	11,901	$4.25M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.7%	43,561	21,822	$4.01M
80363		<1%	2,439	1,545	$100K
80346		<1%	8,524	4,961	$48K
80362		<1%	5,090	3,149	$18K
80348		<1%	6,716	4,111	$17K
80360		<1%	6,472	4,149	$13K
80357		<1%	5,933	3,458	$13K
80321		<1%	3,580	2,119	$13K

25 more codes

80323	<1%	5,226	$13K
80345	<1%	2,646	$12K
80173	<1%	1,223	$10K
80349	<1%	5,118	$10K
80354	<1%	4,203	$9K
80324	<1%	3,996	$9K
80368	<1%	3,459	$8K
80365	<1%	3,502	$7K
80361	<1%	3,527	$7K
80358	<1%	2,966	$6K
80353	<1%	3,720	$6K
80369	<1%	2,894	$6K
80356	<1%	2,835	$5K
83992	<1%	2,624	$4K
80372	<1%	2,756	$4K
80373	<1%	2,796	$4K
80366	<1%	3,224	$1K
80335	<1%	2,058	$1K
80367	<1%	2,191	$448.29
80355	<1%	5,954	$108.95
80338	0%	327	$0.00
80336	0%	287	$0.00
80375	0%	12	$0.00
80359	0%	292	$0.00
80333	0%	287	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMICHALIK, MATTHEW (CFO)